At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
ART +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Oct 16, 2018·Updated May 4, 2026
In Brief
A Phase 2 clinical trial evaluating ART, VRC01LS, and 1 other intervention for HIV Infection. Completed, enrolled 30 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the impact of two broadly neutralizing antibodies, VRC01LS and 10-1074, on the maintenance of HIV suppression in a cohort of early-treated children in Botswana.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infection
CountriesBotswana
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartJun 2019
Primary CompletionDec 2021
TodayJul 2026
First PostedOct 16, 2018
Enrollment StartJun 17, 2019
Primary CompletionDec 3, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.7 years ago
Interventions
ARTdrug
ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.
VRC01LSbiological
Administered by intravenous (IV) infusion
10-1074biological
Administered by intravenous (IV) infusion